Company name
Ophthanova Therapeutics
Company profile
Ophthanova Therapeutics, a Swiss biotech company, is pioneering neurovascular therapies for retinal diseases with a focus on diabetic retinopathy. Its lead candidate, an anti-NogoA antibody NG050, promotes revascularisation and reduces vascular leakage—key drivers of disease progression. With strong preclinical data Ophthanova is preparing for a Phase 1b trial in 2028. The company has commenced raising a Series A to fund pre-clinical development up to InD.
Date, time and room information
Monday, May 4, 14:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Anti‑Nogo‑A Therapy for Neurovascular Repair in Diabetic Retinopathy
Speaker information
| Name | Position | Institution |
|---|---|---|
| Stefan Moese | CEO | Ophthanova Therapeutics |
